Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Conditions

• Lung Adenocarcinoma
• Lung Adenosquamous Carcinoma
• Lung Large Cell Carcinoma
• Lung Squamous Cell Carcinoma
• Minimally Invasive Lung Adenocarcinoma
• Stage IIIA Lung Non-Small Cell Cancer AJCC v7
• Stage IIIB Lung Non-Small Cell Cancer AJCC v7

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bevacizumab — BIOLOGICAL
  Given IV
• Cisplatin — DRUG
  Given IV
• Docetaxel — DRUG
  Given IV
• Etoposide — DRUG
  Given IV
• Filgrastim — BIOLOGICAL
  Given SC
• Pegfilgrastim — BIOLOGICAL
  Given SC
• Radiation Therapy — RADIATION
  Undergo thoracic radiotherapy

Study Details

This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, work in different ways to stop the growth of \[cancer/tumor\] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving more than one drug (combination chemotherapy) together with radiation therapy and bevacizumab may kill more tumor cells.

Key Dates

First listed

Jun 8, 2006

Start date

Jun 15, 2006

Status verified

Feb 2026

Primary completion

Jul 1, 2014

Completion

Feb 22, 2027

Study Design

Enrollment

29 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Group 1 (cisplatin, etoposide, radiotherapy)
  Patients receive cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
• Experimental: Group 2 (cisplatin, etoposide, radiotherapy, bevacizumab)
  Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
• Experimental: Group 3 (cisplatin, etoposide, radiotherapy, bevacizumab)
  Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.

Primary Outcome Measure

Adverse Events [ Time Frame: Up to one year ]

Locations (61)

Find similar trials in Mobile, AL

Related Studies

• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
  PHASE2 · Recruiting · National Cancer Institute (NCI) · Anchorage, Alaska
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  PHASE1 · Recruiting · Anusha Kalbasi · Duarte, California
• Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
  PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
  PHASE2 · Recruiting · National Cancer Institute (NCI) · Buena Park, California